PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
3109073-3	1987	Continuous drip infusion of gabexate mesilate, a synthetic inhibitor of serine-protease, was found to be successful in managing DIC, followed by the restoration of renal function.	Gabexate	28-45	coagulation factor II, thrombin	Homo sapiens	72-87
3024668-1	1986	In this investigation we studied the inhibitory effect of FOY S 983 (gabexate mesilate) and FOY S 980 (camostate mesilate) on the kininase II activity in human plasma in vitro.	Gabexate	58-61	angiotensin I converting enzyme	Homo sapiens	130-141
2435641-8	1986	Unlike aprotinin and urinastatin, nafamostat and gabexate inhibited alpha 2-macroglobulin bound trypsin as well as free trypsin to the same extent.	Gabexate	49-57	alpha-2-macroglobulin	Homo sapiens	68-89
3024668-1	1986	In this investigation we studied the inhibitory effect of FOY S 983 (gabexate mesilate) and FOY S 980 (camostate mesilate) on the kininase II activity in human plasma in vitro.	Gabexate	92-95	angiotensin I converting enzyme	Homo sapiens	130-141
3926598-0	1985	Inhibitory effect of gabexate mesilate on pancreatic phospholipase A2-mediated hydrolysis of ghost membranes.	Gabexate	21-38	phospholipase A2 group IB	Homo sapiens	53-69
2878899-4	1986	The most active compound, ethyl-p-(6-guanidinohexanoyloxy) benzoate methane sulfonate (EGBM) produced 50% inhibition of human acrosin, goat acrosin, and trypsin at 5.0 X 10(-7), 8.4 X 10(-7), and 6.5 X 10(-7) M concentrations, respectively.	Gabexate	26-85	acrosin	Homo sapiens	126-133
2878899-4	1986	The most active compound, ethyl-p-(6-guanidinohexanoyloxy) benzoate methane sulfonate (EGBM) produced 50% inhibition of human acrosin, goat acrosin, and trypsin at 5.0 X 10(-7), 8.4 X 10(-7), and 6.5 X 10(-7) M concentrations, respectively.	Gabexate	26-85	acrosin	Capra hircus	140-147
3087076-2	1986	We investigated the effect of a new synthetic protease- and phospholipase A2-inhibitor gabexate mesilate (FOY) in a multicenter (6 hospitals in Hannover and vicinity) double-blind study on the clinical course of acute pancreatitis.	Gabexate	87-104	phospholipase A2 group IB	Homo sapiens	60-76
2412725-0	1985	Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis.	Gabexate	0-17	phospholipase A2 group IB	Homo sapiens	51-67
2442741-2	1987	Gabexate mesilate (FOY), a synthetic guanidino acid ester exhibiting potent and versatile inhibitory actions on a number of proteinases (e.g., trypsin, kallikrein, C1-r, C1 esterase, plasmin, thrombin, phospholipase A2), was examined for its ability to protect the rat pancreas against development of AP induced by pharmacological doses of ceruletide (CRT).	Gabexate	0-17	complement C1r	Rattus norvegicus	164-168
2442741-2	1987	Gabexate mesilate (FOY), a synthetic guanidino acid ester exhibiting potent and versatile inhibitory actions on a number of proteinases (e.g., trypsin, kallikrein, C1-r, C1 esterase, plasmin, thrombin, phospholipase A2), was examined for its ability to protect the rat pancreas against development of AP induced by pharmacological doses of ceruletide (CRT).	Gabexate	0-17	complement C1s	Rattus norvegicus	170-181
2442741-2	1987	Gabexate mesilate (FOY), a synthetic guanidino acid ester exhibiting potent and versatile inhibitory actions on a number of proteinases (e.g., trypsin, kallikrein, C1-r, C1 esterase, plasmin, thrombin, phospholipase A2), was examined for its ability to protect the rat pancreas against development of AP induced by pharmacological doses of ceruletide (CRT).	Gabexate	0-17	coagulation factor II	Rattus norvegicus	192-200
2442741-2	1987	Gabexate mesilate (FOY), a synthetic guanidino acid ester exhibiting potent and versatile inhibitory actions on a number of proteinases (e.g., trypsin, kallikrein, C1-r, C1 esterase, plasmin, thrombin, phospholipase A2), was examined for its ability to protect the rat pancreas against development of AP induced by pharmacological doses of ceruletide (CRT).	Gabexate	0-17	phospholipase A2 group IB	Rattus norvegicus	202-218
2442741-2	1987	Gabexate mesilate (FOY), a synthetic guanidino acid ester exhibiting potent and versatile inhibitory actions on a number of proteinases (e.g., trypsin, kallikrein, C1-r, C1 esterase, plasmin, thrombin, phospholipase A2), was examined for its ability to protect the rat pancreas against development of AP induced by pharmacological doses of ceruletide (CRT).	Gabexate	19-22	complement C1r	Rattus norvegicus	164-168
2442741-2	1987	Gabexate mesilate (FOY), a synthetic guanidino acid ester exhibiting potent and versatile inhibitory actions on a number of proteinases (e.g., trypsin, kallikrein, C1-r, C1 esterase, plasmin, thrombin, phospholipase A2), was examined for its ability to protect the rat pancreas against development of AP induced by pharmacological doses of ceruletide (CRT).	Gabexate	19-22	complement C1s	Rattus norvegicus	170-181
2442741-2	1987	Gabexate mesilate (FOY), a synthetic guanidino acid ester exhibiting potent and versatile inhibitory actions on a number of proteinases (e.g., trypsin, kallikrein, C1-r, C1 esterase, plasmin, thrombin, phospholipase A2), was examined for its ability to protect the rat pancreas against development of AP induced by pharmacological doses of ceruletide (CRT).	Gabexate	19-22	coagulation factor II	Rattus norvegicus	192-200
2442741-2	1987	Gabexate mesilate (FOY), a synthetic guanidino acid ester exhibiting potent and versatile inhibitory actions on a number of proteinases (e.g., trypsin, kallikrein, C1-r, C1 esterase, plasmin, thrombin, phospholipase A2), was examined for its ability to protect the rat pancreas against development of AP induced by pharmacological doses of ceruletide (CRT).	Gabexate	19-22	phospholipase A2 group IB	Rattus norvegicus	202-218
3095004-4	1986	These hypotensive effects were completely blocked by the infusion of ethyl-p-(6-guanidinohexanoyloxy) benzoate methanesulfonate (FOY), a kallikrein inhibitor.	Gabexate	69-127	kallikrein related peptidase 4	Homo sapiens	137-147
3095004-4	1986	These hypotensive effects were completely blocked by the infusion of ethyl-p-(6-guanidinohexanoyloxy) benzoate methanesulfonate (FOY), a kallikrein inhibitor.	Gabexate	129-132	kallikrein related peptidase 4	Homo sapiens	137-147
3926598-4	1985	When phosphatidylcholine micelles were incubated with the enzyme in the presence of gabexate mesilate, the mode of inhibition of the enzyme action by the drug appeared to be noncompetitive and Ki of gabexate mesilate for phospholipase A2 was 0.77 mM.	Gabexate	84-101	phospholipase A2 group IB	Homo sapiens	221-237
3926598-4	1985	When phosphatidylcholine micelles were incubated with the enzyme in the presence of gabexate mesilate, the mode of inhibition of the enzyme action by the drug appeared to be noncompetitive and Ki of gabexate mesilate for phospholipase A2 was 0.77 mM.	Gabexate	199-216	phospholipase A2 group IB	Homo sapiens	221-237
6190378-10	1983	Gabexate mesilate inhibits pancreas phospholipase A2 in concentrations more than 10-fold higher than those necessary in the isolated lungs (IC50 = 430 microM), bee venom phospholipase A2 not being affected at all.	Gabexate	0-17	phospholipase A2	Oryctolagus cuniculus	36-52
6433363-0	1984	Effects of the serine protease inhibitor gabexate mesilate on purified pancreatic phospholipase A2.	Gabexate	41-58	phospholipase A2 group IB	Homo sapiens	82-98
6433363-1	1984	The catalytic activity of purified porcine pancreatic phospholipase A2 is competitively inhibited by the cationic amphiphilic serine protease inhibitor gabexate mesilate (ethyl 4-(6-guanidinohexanoyloxy) benzoate methanesulfonate).	Gabexate	152-169	phospholipase A2 group IB	Homo sapiens	54-70
6433363-3	1984	The main metabolites of this drug, 6-guanidinocaproic acid and ethyl p-hydroxy-benzoate, had no effect in concentrations up to 10(-2)M. From the high gabexate mesilate concentrations required to reduce phospholipase A2 activity and from the considerably lower drug concentrations sufficient to cause beneficial effects in acute pancreatitis it is concluded that direct inhibition of pancreatic phospholipase A2 cannot be the cause of the therapeutic results, improvement of the symptoms and prognosis of acute pancreatitis.	Gabexate	150-167	phospholipase A2 group IB	Homo sapiens	202-218
6194800-2	1983	Benzoyl-prolyl-phenylalanyl arginine-p-nitroanilide (PPAN) cleavage of purified plasma K was markedly inhibited by aprotinin and gabexate mesilate, and acetyl-glycyl-l-lysine methyl ester hydrolysis of purified PK activator was slightly inhibited.	Gabexate	129-146	peter pan homolog	Homo sapiens	53-57
6194800-3	1983	PPAN cleavage of plasma K-alpha2 macroglobulin complex was hardly inhibited by aprotinin while PPAN cleavage of the complex was markedly inhibited by gabexate mesilate.	Gabexate	150-167	peter pan homolog	Homo sapiens	95-99
6188559-5	1983	The addition of kallikrein inhibitors (aprotinin and gabexate mesilate) resulted in a significant suppression of enzymatic activity but not of enzyme quantity.	Gabexate	53-70	kallikrein related peptidase 4	Homo sapiens	16-26
6194983-0	1983	Inhibition of phospholipase A2 by gabexate mesilate, camostate and aprotinine.	Gabexate	34-51	phospholipase A2 group IB	Homo sapiens	14-30
6814824-1	1982	Gabexate mesilate (FOY), a synthetic serine proteinase inhibitor, prevented and controlled bleeding during hemodialysis of 3 patients with active bleeding sites and/or hemorrhagic tendencies.	Gabexate	0-17	endogenous retrovirus group K member 25	Homo sapiens	44-54
6814824-1	1982	Gabexate mesilate (FOY), a synthetic serine proteinase inhibitor, prevented and controlled bleeding during hemodialysis of 3 patients with active bleeding sites and/or hemorrhagic tendencies.	Gabexate	19-22	endogenous retrovirus group K member 25	Homo sapiens	44-54
6194089-0	1983	[Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate].	Gabexate	88-105	phospholipase A2 group IB	Homo sapiens	61-77
33791707-6	2021	In doing so, we demonstrate that serine protease inhibitors camostat, nafamostat, and gabexate inhibit through a covalent mechanism.	Gabexate	86-94	coagulation factor II, thrombin	Homo sapiens	33-48
27140710-7	2016	The IL-10 levels on the fourth day were significantly improved in the somatostatin + ulinastatin, the somatostatin + gabexate and the somatostatin + ulinastatin + gabexate subgroups compared with the somatostatin subgroup.	Gabexate	117-125	interleukin 10	Homo sapiens	4-9
31490455-11	2019	CONCLUSIONS: Although our analysis suggests that GAB may be the most effective drug in preventing PEP, the limitations of our study warrants more high-quality head-to-head trials of these clinical drugs in the future.	Gabexate	49-52	progestagen associated endometrial protein	Homo sapiens	98-101
29288468-7	2018	Pretreatment with gabexate mesilate (GM, 100 microM), a serine protease inhibitor, that blocks plasmin"s proteolytic activity, fully suppressed the plasmin-induced Ca2+ response.	Gabexate	18-35	plasminogen	Homo sapiens	95-102
29288468-7	2018	Pretreatment with gabexate mesilate (GM, 100 microM), a serine protease inhibitor, that blocks plasmin"s proteolytic activity, fully suppressed the plasmin-induced Ca2+ response.	Gabexate	18-35	plasminogen	Homo sapiens	148-155
29288468-7	2018	Pretreatment with gabexate mesilate (GM, 100 microM), a serine protease inhibitor, that blocks plasmin"s proteolytic activity, fully suppressed the plasmin-induced Ca2+ response.	Gabexate	37-39	plasminogen	Homo sapiens	95-102
29288468-7	2018	Pretreatment with gabexate mesilate (GM, 100 microM), a serine protease inhibitor, that blocks plasmin"s proteolytic activity, fully suppressed the plasmin-induced Ca2+ response.	Gabexate	37-39	plasminogen	Homo sapiens	148-155
29288468-8	2018	After washout of GM and the first plasmin, the second administration of plasmin caused Ca2+ increases.	Gabexate	17-19	plasminogen	Homo sapiens	72-79
27140710-6	2016	Tumor necrosis factor alpha, IL-6 and IL-8 levels on the fourth day after treatment showed significant decrease in the somatostatin + ulinastatin, the somatostatin + gabexate and the somatostatin + ulinastatin + gabexate subgroups compared with the somatostatin subgroup.	Gabexate	166-174	tumor necrosis factor	Homo sapiens	0-27
27140710-6	2016	Tumor necrosis factor alpha, IL-6 and IL-8 levels on the fourth day after treatment showed significant decrease in the somatostatin + ulinastatin, the somatostatin + gabexate and the somatostatin + ulinastatin + gabexate subgroups compared with the somatostatin subgroup.	Gabexate	166-174	interleukin 6	Homo sapiens	29-33
27140710-6	2016	Tumor necrosis factor alpha, IL-6 and IL-8 levels on the fourth day after treatment showed significant decrease in the somatostatin + ulinastatin, the somatostatin + gabexate and the somatostatin + ulinastatin + gabexate subgroups compared with the somatostatin subgroup.	Gabexate	166-174	C-X-C motif chemokine ligand 8	Homo sapiens	38-42
27140710-6	2016	Tumor necrosis factor alpha, IL-6 and IL-8 levels on the fourth day after treatment showed significant decrease in the somatostatin + ulinastatin, the somatostatin + gabexate and the somatostatin + ulinastatin + gabexate subgroups compared with the somatostatin subgroup.	Gabexate	212-220	tumor necrosis factor	Homo sapiens	0-27
31888315-9	2020	The expressions of p65, proinflammatory cytokines, and iNOS significantly decreased in the gabexate group compared with the vehicle-treated group (P < 0.05) on the 7th day.	Gabexate	91-99	synaptotagmin 1	Rattus norvegicus	19-22
31888315-9	2020	The expressions of p65, proinflammatory cytokines, and iNOS significantly decreased in the gabexate group compared with the vehicle-treated group (P < 0.05) on the 7th day.	Gabexate	91-99	nitric oxide synthase 2	Rattus norvegicus	55-59
27140710-7	2016	The IL-10 levels on the fourth day were significantly improved in the somatostatin + ulinastatin, the somatostatin + gabexate and the somatostatin + ulinastatin + gabexate subgroups compared with the somatostatin subgroup.	Gabexate	163-171	interleukin 10	Homo sapiens	4-9
20830242-7	2010	The cell growth inhibition by gabexate mesilate was almost blocked by caspase 3 inhibitor.	Gabexate	30-47	caspase 3	Homo sapiens	70-79
26038004-9	2015	The CRP level tended to be lower in the rTM group than in the GM group.	Gabexate	62-64	C-reactive protein	Homo sapiens	4-7
24131465-7	2014	Either ENMD1068, a PAR-2 antagonist, or gabexate, a serine protease inhibitor, significantly inhibited S1P-induced vasorelaxation.	Gabexate	40-48	sphingosine-1-phosphate receptor 1	Mus musculus	103-106
24201777-8	2014	This effect was related to inhibition of gemcitabine-induced NF-kappaB activation by gabexate mesilate, which prevented RelA/p65 nuclear translocation and resulted in metalloproteinase 2, metalloproteinase 9, vascular endothelial growth factor, and interleukin 8 down-regulation.	Gabexate	85-102	RELA proto-oncogene, NF-kB subunit	Homo sapiens	125-128
24201777-8	2014	This effect was related to inhibition of gemcitabine-induced NF-kappaB activation by gabexate mesilate, which prevented RelA/p65 nuclear translocation and resulted in metalloproteinase 2, metalloproteinase 9, vascular endothelial growth factor, and interleukin 8 down-regulation.	Gabexate	85-102	vascular endothelial growth factor A	Homo sapiens	209-243
24201777-8	2014	This effect was related to inhibition of gemcitabine-induced NF-kappaB activation by gabexate mesilate, which prevented RelA/p65 nuclear translocation and resulted in metalloproteinase 2, metalloproteinase 9, vascular endothelial growth factor, and interleukin 8 down-regulation.	Gabexate	85-102	C-X-C motif chemokine ligand 8	Homo sapiens	249-262
24201777-9	2014	Combined treatment with gabexate mesilate also inhibited gemcitabine-induced extracellular-regulated kinase 1/2 and AKT activation by increased expression of Raf kinase inhibitor protein and phosphatase and tensin homolog.	Gabexate	24-41	AKT serine/threonine kinase 1	Homo sapiens	116-119
22911782-5	2012	Results obtained showed that gabexate mesilate significantly inhibited the growth, invasive potential and tumour-induced angiogenesis in all the CRC cells employed in this study (including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA mutation), while cetuximab affected these parameters only in CRC cells with KRAS, BRAF and PIK3CA wild-type.	Gabexate	29-46	KRAS proto-oncogene, GTPase	Homo sapiens	216-220
22911782-5	2012	Results obtained showed that gabexate mesilate significantly inhibited the growth, invasive potential and tumour-induced angiogenesis in all the CRC cells employed in this study (including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA mutation), while cetuximab affected these parameters only in CRC cells with KRAS, BRAF and PIK3CA wild-type.	Gabexate	29-46	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	221-227
22911782-5	2012	Results obtained showed that gabexate mesilate significantly inhibited the growth, invasive potential and tumour-induced angiogenesis in all the CRC cells employed in this study (including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA mutation), while cetuximab affected these parameters only in CRC cells with KRAS, BRAF and PIK3CA wild-type.	Gabexate	29-46	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	231-235
22911782-5	2012	Results obtained showed that gabexate mesilate significantly inhibited the growth, invasive potential and tumour-induced angiogenesis in all the CRC cells employed in this study (including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA mutation), while cetuximab affected these parameters only in CRC cells with KRAS, BRAF and PIK3CA wild-type.	Gabexate	29-46	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	236-242
22911782-5	2012	Results obtained showed that gabexate mesilate significantly inhibited the growth, invasive potential and tumour-induced angiogenesis in all the CRC cells employed in this study (including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA mutation), while cetuximab affected these parameters only in CRC cells with KRAS, BRAF and PIK3CA wild-type.	Gabexate	29-46	KRAS proto-oncogene, GTPase	Homo sapiens	319-323
22911782-5	2012	Results obtained showed that gabexate mesilate significantly inhibited the growth, invasive potential and tumour-induced angiogenesis in all the CRC cells employed in this study (including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA mutation), while cetuximab affected these parameters only in CRC cells with KRAS, BRAF and PIK3CA wild-type.	Gabexate	29-46	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	325-329
22911782-5	2012	Results obtained showed that gabexate mesilate significantly inhibited the growth, invasive potential and tumour-induced angiogenesis in all the CRC cells employed in this study (including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA mutation), while cetuximab affected these parameters only in CRC cells with KRAS, BRAF and PIK3CA wild-type.	Gabexate	29-46	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	236-242
22911782-7	2012	Overall, these preliminary findings suggest that gabexate mesilate could represent a promising therapeutic option for mCRC patients, particularly for those harbouring KRAS, BRAF and PIK3CA mutations, either as mono-therapy or in addition to standard chemotherapy regimens.	Gabexate	49-66	KRAS proto-oncogene, GTPase	Homo sapiens	167-171
22911782-7	2012	Overall, these preliminary findings suggest that gabexate mesilate could represent a promising therapeutic option for mCRC patients, particularly for those harbouring KRAS, BRAF and PIK3CA mutations, either as mono-therapy or in addition to standard chemotherapy regimens.	Gabexate	49-66	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	173-177
22911782-7	2012	Overall, these preliminary findings suggest that gabexate mesilate could represent a promising therapeutic option for mCRC patients, particularly for those harbouring KRAS, BRAF and PIK3CA mutations, either as mono-therapy or in addition to standard chemotherapy regimens.	Gabexate	49-66	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	182-188
19766246-0	2011	Gabexate mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.	Gabexate	0-17	high mobility group box 1	Rattus norvegicus	45-50
19766246-3	2011	We aimed to evaluate the effect of GM on HMGB1 in lipopolysaccharide (LPS)-induced lung injury in rats.	Gabexate	35-37	high mobility group box 1	Rattus norvegicus	41-46
19766246-8	2011	Furthermore, LPS-induced increases in PAI-1 and PAR-2 activity and in plasma HMGB1 concentrations were lower in the rats given both GM and LPS than in the rats given LPS alone.	Gabexate	132-134	serpin family E member 1	Rattus norvegicus	38-43
19766246-8	2011	Furthermore, LPS-induced increases in PAI-1 and PAR-2 activity and in plasma HMGB1 concentrations were lower in the rats given both GM and LPS than in the rats given LPS alone.	Gabexate	132-134	F2R like trypsin receptor 1	Rattus norvegicus	48-53
19766246-8	2011	Furthermore, LPS-induced increases in PAI-1 and PAR-2 activity and in plasma HMGB1 concentrations were lower in the rats given both GM and LPS than in the rats given LPS alone.	Gabexate	132-134	high mobility group box 1	Rattus norvegicus	77-82
19766246-9	2011	Release of HMGB1 and cytokines from the cell after the administration of LPS were decreased by GM.	Gabexate	95-97	high mobility group box 1	Rattus norvegicus	11-16
19766246-11	2011	GM may have inhibited PAI-1 and PAR-2, thereby indirectly inhibiting HMGB1 and reducing tissue damage in the lung.	Gabexate	0-2	serpin family E member 1	Rattus norvegicus	22-27
19766246-11	2011	GM may have inhibited PAI-1 and PAR-2, thereby indirectly inhibiting HMGB1 and reducing tissue damage in the lung.	Gabexate	0-2	F2R like trypsin receptor 1	Rattus norvegicus	32-37
19766246-11	2011	GM may have inhibited PAI-1 and PAR-2, thereby indirectly inhibiting HMGB1 and reducing tissue damage in the lung.	Gabexate	0-2	high mobility group box 1	Rattus norvegicus	69-74
25354693-5	2015	Derivatized products of octreotide and gabexate mesylate metabolite were separated on a Luna C18 column (4.6 x 250 mm; 5 microm particle size) using a gradient with a run time of 36 min, without further purification.	Gabexate	39-56	Bardet-Biedl syndrome 9	Homo sapiens	93-96
25354693-8	2015	Derivatized products of octreotide and gabexate mesylate metabolite were separated on a Luna C18 column (4.6 x 250 mm; 5 microm particle size) using a gradient with a run time of 36 min, without further purification.	Gabexate	39-56	Bardet-Biedl syndrome 9	Homo sapiens	93-96
22204993-7	2012	Antithrombin increased to the normal level on day 1 in the antithrombin group but on day 7 in the gabexate mesilate group.	Gabexate	98-115	serpin family C member 1	Homo sapiens	0-12
20649759-5	2010	Granulocyte adsorption and IL-1ra release were significantly suppressed with increasing gabexate mesilate concentrations; however, the adsorption was not significantly inhibited by ulinastatin.	Gabexate	88-105	interleukin 1 receptor antagonist	Homo sapiens	27-33
20594263-8	2010	RESULTS: In rats with acute liver failure, GM treatment significantly decreased the plasma levels of alanine aminotransferase (P = 0.02), but no significant difference of motor activity, plasma levels of ammonia, IL-1beta, IL-6, IL-10 and TNF-alpha or survival was found.	Gabexate	43-45	interleukin 6	Rattus norvegicus	223-227
20594263-8	2010	RESULTS: In rats with acute liver failure, GM treatment significantly decreased the plasma levels of alanine aminotransferase (P = 0.02), but no significant difference of motor activity, plasma levels of ammonia, IL-1beta, IL-6, IL-10 and TNF-alpha or survival was found.	Gabexate	43-45	interleukin 10	Rattus norvegicus	229-234
20594263-8	2010	RESULTS: In rats with acute liver failure, GM treatment significantly decreased the plasma levels of alanine aminotransferase (P = 0.02), but no significant difference of motor activity, plasma levels of ammonia, IL-1beta, IL-6, IL-10 and TNF-alpha or survival was found.	Gabexate	43-45	tumor necrosis factor	Rattus norvegicus	239-248
20594263-9	2010	In chronic liver failure rats, GM significantly lowered the plasma TNF-alpha levels (P = 0.04).	Gabexate	31-33	tumor necrosis factor	Rattus norvegicus	67-76
16557390-7	2006	MDA values and the testicular injury score decreased and SOD, CAT and GSH-Px values increased in the GM-treated group compared to the I-R/untreated group.	Gabexate	101-103	catalase	Rattus norvegicus	62-65
17625304-9	2007	Gabexate mesilate inhibited not only the enzymatic activities of tumor-associated trypsinogen and urokinase-type plasminogen activator but also the production of MMP-2, all of which have been known to be secondarily up-regulated by TGF-beta1.	Gabexate	0-17	plasminogen activator, urokinase	Homo sapiens	98-134
17625304-9	2007	Gabexate mesilate inhibited not only the enzymatic activities of tumor-associated trypsinogen and urokinase-type plasminogen activator but also the production of MMP-2, all of which have been known to be secondarily up-regulated by TGF-beta1.	Gabexate	0-17	matrix metallopeptidase 2	Homo sapiens	162-167
17625304-9	2007	Gabexate mesilate inhibited not only the enzymatic activities of tumor-associated trypsinogen and urokinase-type plasminogen activator but also the production of MMP-2, all of which have been known to be secondarily up-regulated by TGF-beta1.	Gabexate	0-17	transforming growth factor beta 1	Homo sapiens	232-241
19249478-0	2009	C5a inhibitory peptide combined with gabexate mesilate is a clinically available candidate for preventing the instant blood-mediated inflammatory reaction.	Gabexate	37-54	complement C5	Rattus norvegicus	0-3
24692807-2	2008	Although prophylactic use of gabexate mesylate (GM) for the reduction of pancreatic injury after ERCP has been evaluated, uncertainty remains regarding the effectiveness of GM treatment in post-ERCP pancreatitis (PEP).	Gabexate	173-175	prolyl endopeptidase	Homo sapiens	213-216
24692807-3	2008	OBJECTIVE: The aim of this study was to determine through systematic review and meta-analysis the effectiveness and tolerability of GM in the prophylaxis of PEP.	Gabexate	132-134	prolyl endopeptidase	Homo sapiens	157-160
24692807-5	2008	We used the method recommended by The Cochrane Collaboration to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) of GM in the prevention of PEP.	Gabexate	152-154	prolyl endopeptidase	Homo sapiens	176-179
17357832-0	2007	Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-kappaB activation and increases TNF-alpha-mediated apoptosis in human pancreatic cancer cells.	Gabexate	37-54	tumor necrosis factor	Homo sapiens	112-121
17357832-6	2007	The NF-kappaB activity of both cell lines was increased by the addition of TNF-alpha, while TNF-alpha-induced NF-kappaB activity was suppressed by prestimulation with GM in a dose-dependent manner.	Gabexate	167-169	tumor necrosis factor	Homo sapiens	92-101
17357832-7	2007	Caspase 3 and 7 activity was significantly increased by TNF-alpha with GM stimulation.	Gabexate	71-73	caspase 3	Homo sapiens	0-9
17357832-7	2007	Caspase 3 and 7 activity was significantly increased by TNF-alpha with GM stimulation.	Gabexate	71-73	tumor necrosis factor	Homo sapiens	56-65
17357832-9	2007	These results indicate that GM inhibits TNF-alpha-induced NF-kappaB activation and enhances apoptosis in human pancreatic cancer cell lines.	Gabexate	28-30	tumor necrosis factor	Homo sapiens	40-49
16815145-0	2006	Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma.	Gabexate	51-68	complement component 1, s subcomponent 1	Mus musculus	0-15
15257104-7	2004	GM inhibited not only the enzymatic activities of TAT and u-PA but also the production of MMP-2, and u-PA, all of which have been known to be secondarily down-regulated by TGF-beta1.	Gabexate	0-2	plasminogen activator, urokinase	Homo sapiens	58-62
16473521-13	2006	Gabexate mesilate significantly reduced serum levels of amylase, lipase, tumor necrosis factor alpha and interleukin-6 at 5 h. Serum levels of interleukin-10 significantly increased in Group I, as compared with Groups II and III.	Gabexate	0-17	lipase G, endothelial type	Rattus norvegicus	65-71
16473521-13	2006	Gabexate mesilate significantly reduced serum levels of amylase, lipase, tumor necrosis factor alpha and interleukin-6 at 5 h. Serum levels of interleukin-10 significantly increased in Group I, as compared with Groups II and III.	Gabexate	0-17	tumor necrosis factor	Rattus norvegicus	73-100
16473521-13	2006	Gabexate mesilate significantly reduced serum levels of amylase, lipase, tumor necrosis factor alpha and interleukin-6 at 5 h. Serum levels of interleukin-10 significantly increased in Group I, as compared with Groups II and III.	Gabexate	0-17	interleukin 6	Rattus norvegicus	105-118
16473521-13	2006	Gabexate mesilate significantly reduced serum levels of amylase, lipase, tumor necrosis factor alpha and interleukin-6 at 5 h. Serum levels of interleukin-10 significantly increased in Group I, as compared with Groups II and III.	Gabexate	0-17	interleukin 10	Rattus norvegicus	143-157
15830285-2	2005	The aim of the present study was to investigate the effect of gabexate mesilate in carbon tetrachloride (CCl4)-induced liver injury in rats.	Gabexate	62-79	C-C motif chemokine ligand 4	Rattus norvegicus	105-109
15830285-5	2005	RESULTS: Gabexate mesilate treatment significantly decreased the elevation of serum transaminase levels and improved liver histology 24 h after the administration of CCl4 (0.2 ml/100 g rat weight).	Gabexate	9-26	C-C motif chemokine ligand 4	Rattus norvegicus	166-170
15830285-6	2005	Plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) decreased significantly in the gabexate mesilate-treated rats compared with saline-treated rats.	Gabexate	111-128	tumor necrosis factor	Rattus norvegicus	7-34
15830285-6	2005	Plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) decreased significantly in the gabexate mesilate-treated rats compared with saline-treated rats.	Gabexate	111-128	tumor necrosis factor	Rattus norvegicus	36-45
15830285-6	2005	Plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) decreased significantly in the gabexate mesilate-treated rats compared with saline-treated rats.	Gabexate	111-128	interleukin 1 beta	Rattus norvegicus	51-68
15830285-6	2005	Plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) decreased significantly in the gabexate mesilate-treated rats compared with saline-treated rats.	Gabexate	111-128	interleukin 1 beta	Rattus norvegicus	70-78
15830285-7	2005	Gabexate mesilate treatment also significantly improved survival rate after a lethal dose of CCl4 (0.5 ml/100 g rat weight) from 0% to 20%.	Gabexate	0-17	C-C motif chemokine ligand 4	Rattus norvegicus	93-97
15830285-8	2005	CONCLUSIONS: Gabexate mesilate treatment attenuated CCl4-induced liver injury via a suppression of proinflammatory cytokine production.	Gabexate	13-30	C-C motif chemokine ligand 4	Rattus norvegicus	52-56
16198632-3	2005	The use of proteinase inhibitors such as gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (ERCP) has been disappointing.	Gabexate	41-58	endogenous retrovirus group K member 18	Homo sapiens	11-21
15906759-10	2005	The enzyme inhibition in the pancreatic gland itself and the central role of inhibition of phospholipase A2 in the enzyme cascade responsible for activating other proteases, confirm the therapeutic use of GM in acute pancreatitis.	Gabexate	205-207	phospholipase A2 group IB	Homo sapiens	91-107
15257104-7	2004	GM inhibited not only the enzymatic activities of TAT and u-PA but also the production of MMP-2, and u-PA, all of which have been known to be secondarily down-regulated by TGF-beta1.	Gabexate	0-2	matrix metallopeptidase 2	Homo sapiens	90-95
15257104-7	2004	GM inhibited not only the enzymatic activities of TAT and u-PA but also the production of MMP-2, and u-PA, all of which have been known to be secondarily down-regulated by TGF-beta1.	Gabexate	0-2	plasminogen activator, urokinase	Homo sapiens	101-105
15257104-7	2004	GM inhibited not only the enzymatic activities of TAT and u-PA but also the production of MMP-2, and u-PA, all of which have been known to be secondarily down-regulated by TGF-beta1.	Gabexate	0-2	transforming growth factor beta 1	Homo sapiens	172-181
15240544-3	2004	In this study, we investigated the effect of GM on MMPs and on the invasion and metastasis of human colon cancer cell lines and neoangiogenesis.	Gabexate	45-47	matrix metallopeptidase 2	Homo sapiens	51-55
15240544-4	2004	The activities of MMPs secreted from these cells were significantly reduced by GM but unaffected by the serine protease inhibitor aprotinin.	Gabexate	79-81	matrix metallopeptidase 2	Homo sapiens	18-22
15240544-5	2004	GM directly inhibited purified progelatinase A derived from T98G human glioblastoma cells.	Gabexate	0-2	matrix metallopeptidase 2	Homo sapiens	31-46
15240544-10	2004	These results suggest that GM is a novel inhibitor of MMPs and that it may inhibit the invasion and metastasis of human colon cancer cells by blocking MMPs and neoangiogenesis.	Gabexate	27-29	matrix metallopeptidase 2	Homo sapiens	54-58
15240544-10	2004	These results suggest that GM is a novel inhibitor of MMPs and that it may inhibit the invasion and metastasis of human colon cancer cells by blocking MMPs and neoangiogenesis.	Gabexate	27-29	matrix metallopeptidase 2	Homo sapiens	151-155
12682486-2	2003	We examined whether gabexate mesilate inhibits tumor necrosis factor-alpha-induced expression of leukocyte adhesion molecules in cultured endothelial cells.	Gabexate	20-37	tumor necrosis factor	Homo sapiens	47-74
14976449-5	2004	This was measured using individual dose/response tests with a heparin monitoring system before and after a 10-minute intravenous infusion of 2 mg.kg-1.h-1 of gabexate mesilate, a direct inhibitor of factor Xa, thrombin, kallikrein, and other serine proteases.	Gabexate	158-175	coagulation factor X	Homo sapiens	199-208
14976449-5	2004	This was measured using individual dose/response tests with a heparin monitoring system before and after a 10-minute intravenous infusion of 2 mg.kg-1.h-1 of gabexate mesilate, a direct inhibitor of factor Xa, thrombin, kallikrein, and other serine proteases.	Gabexate	158-175	coagulation factor II, thrombin	Homo sapiens	210-218
14976449-5	2004	This was measured using individual dose/response tests with a heparin monitoring system before and after a 10-minute intravenous infusion of 2 mg.kg-1.h-1 of gabexate mesilate, a direct inhibitor of factor Xa, thrombin, kallikrein, and other serine proteases.	Gabexate	158-175	kallikrein related peptidase 4	Homo sapiens	220-230
14708545-0	2003	Gabexate mesilate (FOY) inhibition of amylase and phospholipase A(2) activity in sow pancreatic juice.	Gabexate	0-17	phospholipase A2 group IB	Homo sapiens	50-68
14708545-5	2003	GM inhibited the two pancreatic enzymes amylase and phospholipase A(2) (PA(2)) in pancreatic juice.	Gabexate	0-2	phospholipase A2 group IB	Homo sapiens	52-70
12682486-12	2003	MEASUREMENTS AND MAIN RESULTS: Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced increases in the endothelial expression of E-selectin and intercellular adhesion molecule-1 by inhibiting the transcription.	Gabexate	31-48	tumor necrosis factor	Homo sapiens	63-90
12682486-13	2003	Tumor necrosis factor-alpha-induced increase in DNA binding of p65 was inhibited by gabexate mesilate through inhibition of the nuclear translocation of p65.	Gabexate	84-101	tumor necrosis factor	Homo sapiens	0-27
12682486-13	2003	Tumor necrosis factor-alpha-induced increase in DNA binding of p65 was inhibited by gabexate mesilate through inhibition of the nuclear translocation of p65.	Gabexate	84-101	RELA proto-oncogene, NF-kB subunit	Homo sapiens	63-66
12682486-13	2003	Tumor necrosis factor-alpha-induced increase in DNA binding of p65 was inhibited by gabexate mesilate through inhibition of the nuclear translocation of p65.	Gabexate	84-101	RELA proto-oncogene, NF-kB subunit	Homo sapiens	153-156
12682486-14	2003	Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced degradation of IkappaBalpha, an inhibitor of nuclear factor-kappaB, by inhibiting phosphorylation of IkappaBalpha in HUVECs.	Gabexate	0-17	tumor necrosis factor	Homo sapiens	32-59
12682486-14	2003	Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced degradation of IkappaBalpha, an inhibitor of nuclear factor-kappaB, by inhibiting phosphorylation of IkappaBalpha in HUVECs.	Gabexate	0-17	NFKB inhibitor alpha	Homo sapiens	83-95
12682486-14	2003	Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced degradation of IkappaBalpha, an inhibitor of nuclear factor-kappaB, by inhibiting phosphorylation of IkappaBalpha in HUVECs.	Gabexate	0-17	NFKB inhibitor alpha	Homo sapiens	169-181
12682486-17	2003	Gabexate mesilate might reduce lipopolysaccharide-induced pulmonary vascular injury not only by inhibiting monocytic tumor necrosis factor-alpha production but by inhibiting the expression of endothelial leukocyte adhesion molecules.	Gabexate	0-17	tumor necrosis factor	Homo sapiens	117-144
12649382-0	2003	Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes.	Gabexate	0-17	tumor necrosis factor	Homo sapiens	87-114
12649382-0	2003	Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes.	Gabexate	0-17	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	185-204
12649382-1	2003	Gabexate mesilate, a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role.	Gabexate	0-17	tumor necrosis factor	Homo sapiens	169-196
12649382-1	2003	Gabexate mesilate, a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role.	Gabexate	0-17	tumor necrosis factor	Homo sapiens	198-207
12649382-3	2003	In the present study, we analyzed the mechanism(s) by which gabexate mesilate inhibits LPS-induced TNF-alpha production in human monocytes in vitro.	Gabexate	60-77	tumor necrosis factor	Homo sapiens	99-108
12649382-4	2003	Gabexate mesilate inhibited the production of TNF-alpha in monocytes stimulated with LPS.	Gabexate	0-17	tumor necrosis factor	Homo sapiens	46-55
12649382-6	2003	Gabexate mesilate also inhibited both the binding of activator protein-1 (AP-1) to target sites and the activation of mitogen-activated protein kinase pathways.	Gabexate	0-17	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	53-72
12649382-6	2003	Gabexate mesilate also inhibited both the binding of activator protein-1 (AP-1) to target sites and the activation of mitogen-activated protein kinase pathways.	Gabexate	0-17	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-78
12649382-7	2003	These observations strongly suggest that gabexate mesilate inhibited LPS-induced TNF-alpha production in human monocytes by inhibiting activation of both NF-kappaB and AP-1.	Gabexate	41-58	tumor necrosis factor	Homo sapiens	81-90
12649382-7	2003	These observations strongly suggest that gabexate mesilate inhibited LPS-induced TNF-alpha production in human monocytes by inhibiting activation of both NF-kappaB and AP-1.	Gabexate	41-58	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	168-172
12649382-8	2003	Inhibition of TNF-alpha production by gabexate mesilate might explain at least partly its therapeutic effects in animals given LPS and those in patients with sepsis.	Gabexate	38-55	tumor necrosis factor	Homo sapiens	14-23
12642398-3	2003	(3) Both gabexate mesilate and nafamostat mesilate inhibited the activity of purified human lung tryptase, although the latter compound was far more potent than the former.	Gabexate	9-26	tryptase alpha/beta 1	Rattus norvegicus	97-105
11172730-0	2001	Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug.	Gabexate	52-69	tryptase delta 1	Homo sapiens	30-48
12113544-6	2002	Preoperative administration of gabexate mesilate (preop GM group) substantially ameliorated hepatic I/R injury as compared with the other patients (intraop and without GM groups); postoperative serum transaminase levels were notably decreased in association with marked suppression of IL-6 levels in blood circulation during liver surgery.	Gabexate	31-48	interleukin 6	Homo sapiens	285-289
12113544-9	2002	CONCLUSIONS: Preoperative administration of GM is useful for preventing I/R injury of the human liver, accompanied by suppression of the plasma proinflammatory cytokine IL-6.	Gabexate	44-46	interleukin 6	Homo sapiens	169-173
12165796-2	2002	To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9.	Gabexate	129-137	matrix metallopeptidase 9	Homo sapiens	155-160
12025532-6	2002	The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4.	Gabexate	25-42	tumor necrosis factor	Homo sapiens	95-104
12025532-6	2002	The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4.	Gabexate	25-42	interleukin 18	Homo sapiens	110-124
12025532-6	2002	The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4.	Gabexate	25-42	interleukin 18	Homo sapiens	126-131
12025532-6	2002	The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4.	Gabexate	25-42	tumor necrosis factor	Homo sapiens	293-302
12025532-6	2002	The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4.	Gabexate	25-42	interleukin 18	Homo sapiens	311-316
12025532-6	2002	The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4.	Gabexate	25-42	toll like receptor 2	Homo sapiens	344-349
12025532-6	2002	The results suggest that gabexate mesilate-induced inhibition of tumour necrosis factor-alpha (TNF-alpha) and interleukin-18 (IL-18) production in LPS-stimulated PBMCs is due to the inhibition of the nuclear factor-kappa B activation pathway and/or inhibition of the processing pathway of pro-TNF-alpha and pro-IL-18, not to down-regulation of TLR-2 or TLR-4.	Gabexate	25-42	toll like receptor 4	Homo sapiens	353-358
11220636-8	2001	GM decreased the TNFalpha production of LPS-stimulated monocytes as shown by the inhibition of mRNA expression and increased the IL-10 production of LPS-stimulated monocytes.	Gabexate	0-2	tumor necrosis factor	Homo sapiens	17-25
11220636-9	2001	GM also suppressed the NFkappaB activity of LPS-stimulated monocytes.	Gabexate	0-2	nuclear factor kappa B subunit 1	Homo sapiens	23-31
11220636-8	2001	GM decreased the TNFalpha production of LPS-stimulated monocytes as shown by the inhibition of mRNA expression and increased the IL-10 production of LPS-stimulated monocytes.	Gabexate	0-2	interleukin 10	Homo sapiens	129-134
8681572-14	1996	Gabexate mesilate significantly inhibited the endotoxin-induced increase in the serum concentration of TNF-alpha in vivo and, at a concentration of 10(-8) M, the production of TNF-alpha by endotoxin-stimulated monocytes in vitro.	Gabexate	0-17	tumor necrosis factor	Rattus norvegicus	103-112
11220636-11	2001	The present study shows that the inhibitory effect of GM on the TNFalpha production of activated human monocytes is mediated by the suppression of NFkappaB activation, while the mechanism of UTI inhibiting TNFalpha production of human monocytes may be due to the inhibition of either the translation or secretion of TNFalpha.	Gabexate	54-56	tumor necrosis factor	Homo sapiens	64-72
11220636-11	2001	The present study shows that the inhibitory effect of GM on the TNFalpha production of activated human monocytes is mediated by the suppression of NFkappaB activation, while the mechanism of UTI inhibiting TNFalpha production of human monocytes may be due to the inhibition of either the translation or secretion of TNFalpha.	Gabexate	54-56	nuclear factor kappa B subunit 1	Homo sapiens	147-155
10037314-6	1999	RESULTS: Time courses of serum IL-6 levels in the preop GM group were significantly lower than those in the postop GM group.	Gabexate	56-58	interleukin 6	Homo sapiens	31-35
10037314-8	1999	Gabexate mesilate showed a little inhibition of TNF-alpha production by monocyte without LPS stimulation.	Gabexate	0-17	tumor necrosis factor	Homo sapiens	48-57
10037314-9	1999	On the other hand, gabexate mesilate significantly inhibited TNF-alpha production by LPS stimulated monocyte.	Gabexate	19-36	tumor necrosis factor	Homo sapiens	61-70
10037314-10	1999	Mac-1 antigen expression by monocyte immediately after operation in the preop GM group was significantly lower than that in the postop GM group.	Gabexate	78-80	integrin subunit alpha M	Homo sapiens	0-5
10037314-10	1999	Mac-1 antigen expression by monocyte immediately after operation in the preop GM group was significantly lower than that in the postop GM group.	Gabexate	135-137	integrin subunit alpha M	Homo sapiens	0-5
10037314-12	1999	CONCLUSIONS: Reduction of systemic inflammatory response syndrome duration after esophagectomy by the continuous administration of gabexate mesilate started before operation may be through the suppression of TNF-alpha production capacity and Mac-1 expression on monocytes immediately after operation, and to suppression of increase in serum IL-6 level.	Gabexate	131-148	tumor necrosis factor	Homo sapiens	208-217
10037314-12	1999	CONCLUSIONS: Reduction of systemic inflammatory response syndrome duration after esophagectomy by the continuous administration of gabexate mesilate started before operation may be through the suppression of TNF-alpha production capacity and Mac-1 expression on monocytes immediately after operation, and to suppression of increase in serum IL-6 level.	Gabexate	131-148	integrin subunit alpha M	Homo sapiens	242-247
10037314-12	1999	CONCLUSIONS: Reduction of systemic inflammatory response syndrome duration after esophagectomy by the continuous administration of gabexate mesilate started before operation may be through the suppression of TNF-alpha production capacity and Mac-1 expression on monocytes immediately after operation, and to suppression of increase in serum IL-6 level.	Gabexate	131-148	interleukin 6	Homo sapiens	341-345
9878311-10	1998	RESULTS: GM inhibited the PAI-1 synthesis of HUVECs stimulated with TNFalpha in a dose-dependent manner as shown by the mRNA expression.	Gabexate	9-11	serpin family E member 1	Homo sapiens	26-31
9878311-10	1998	RESULTS: GM inhibited the PAI-1 synthesis of HUVECs stimulated with TNFalpha in a dose-dependent manner as shown by the mRNA expression.	Gabexate	9-11	tumor necrosis factor	Homo sapiens	68-76
9878311-12	1998	In contrast, both GM and UTI significantly inhibited the ICAM-1 expression on HUVECs stimulated with TNFalpha.	Gabexate	18-20	intercellular adhesion molecule 1	Homo sapiens	57-63
9878311-12	1998	In contrast, both GM and UTI significantly inhibited the ICAM-1 expression on HUVECs stimulated with TNFalpha.	Gabexate	18-20	tumor necrosis factor	Homo sapiens	101-109
9825309-0	1998	Competitive inhibition of Lens culinaris L. copper amine oxidase by amiloride, p-aminobenzamidine, clonidine, 4",6-diamidino-2-phenylindole and gabexate mesylate: a comparative study.	Gabexate	144-161	amine oxidase copper containing 3	Homo sapiens	44-64
9825309-2	1998	However, values of Ki for amiloride and gabexate mesylate binding to swine kidney copper amine oxidase are lower than those observed for inhibitor binding to Lens culinaris L. cooper amine oxidase.	Gabexate	40-48	amine oxidase copper containing 3	Homo sapiens	82-102
9825309-3	1998	Thus, amiloride and gabexate mesylate may represent useful model compounds for the development of selective inhibitors of mammalian copper amine oxidase, which may be important in view of the potential use of plant copper amine oxidase as drugs.	Gabexate	20-37	amine oxidase copper containing 3	Homo sapiens	132-152
9825309-3	1998	Thus, amiloride and gabexate mesylate may represent useful model compounds for the development of selective inhibitors of mammalian copper amine oxidase, which may be important in view of the potential use of plant copper amine oxidase as drugs.	Gabexate	20-37	amine oxidase copper containing 3	Homo sapiens	215-235
9308324-10	1997	Gabexate mesilate significantly improved pathologic criteria and decreased serum lipase levels at doses of 1 and 10 mg/kg/h.	Gabexate	0-17	lipase G, endothelial type	Rattus norvegicus	81-87
21533474-4	1997	Gabexate mesilate significantly reduced the u-PA activity, invasiveness, and hepatic metastasis of SW1990 cells.	Gabexate	0-17	plasminogen activator, urokinase	Homo sapiens	44-48
10499652-7	1999	The total heparin dosage was less in group GA than in groups A and C. Purified AT-III administration is recommended in heparin pretreated patients; the addition of gabexate mesilate to this protocol decreases the heparin requirement and increases the AT-III preservation.	Gabexate	164-181	serpin family C member 1	Homo sapiens	251-257
9610382-2	1998	Gabexate mesylate inhibits competitively constitutive and inducible NO synthase (cNOS and iNOS, respectively), with Ki values of 1.0 x 10(-4) M and 5.0 x 10(-3) M, respectively, at pH 7.4 and 37.0 degrees C. However, gabexate mesylate is not an NO precursor.	Gabexate	0-17	nitric oxide synthase 3	Rattus norvegicus	81-85
9610382-2	1998	Gabexate mesylate inhibits competitively constitutive and inducible NO synthase (cNOS and iNOS, respectively), with Ki values of 1.0 x 10(-4) M and 5.0 x 10(-3) M, respectively, at pH 7.4 and 37.0 degrees C. However, gabexate mesylate is not an NO precursor.	Gabexate	0-17	nitric oxide synthase 2	Rattus norvegicus	90-94
9610382-2	1998	Gabexate mesylate inhibits competitively constitutive and inducible NO synthase (cNOS and iNOS, respectively), with Ki values of 1.0 x 10(-4) M and 5.0 x 10(-3) M, respectively, at pH 7.4 and 37.0 degrees C. However, gabexate mesylate is not an NO precursor.	Gabexate	217-234	nitric oxide synthase 3	Rattus norvegicus	81-85
9610382-3	1998	Moreover, like other NOS inhibitors, gabexate mesylate increases iNOS mRNA expression in rat C6 glioma cells, as induced by E. coli lipopolysaccharide plus interferon-gamma.	Gabexate	37-54	nitric oxide synthase 2	Rattus norvegicus	65-69
8681572-14	1996	Gabexate mesilate significantly inhibited the endotoxin-induced increase in the serum concentration of TNF-alpha in vivo and, at a concentration of 10(-8) M, the production of TNF-alpha by endotoxin-stimulated monocytes in vitro.	Gabexate	0-17	tumor necrosis factor	Rattus norvegicus	176-185
8681572-15	1996	CONCLUSION: Our findings suggest that gabexate mesilate attenuated endotoxin-induced pulmonary vascular injury mainly by inhibiting TNF-alpha production by monocytes, which may play a central role in sepsis-related lung injury.	Gabexate	38-55	tumor necrosis factor	Rattus norvegicus	132-141
1326018-3	1992	Compared to control buffer without protease inhibitor, gabexate mesylate (322 micrograms/ml) caused about a 10-fold increase in intracellular CL in stimulated neutrophils, and ulinastatin (3100 U/ml) a twofold increase in neutrophils stimulated with fMLP or IL-8.	Gabexate	55-72	C-X-C motif chemokine ligand 8	Homo sapiens	258-262
8749319-2	1995	We found that gabexate mesilate suppressed SOD-inhibitable cytochrome c reduction in a dose-dependent manner in intact neutrophils activated with phorbol ester.	Gabexate	14-31	cytochrome c, somatic	Homo sapiens	59-71
7890006-0	1995	Effect of gabexate mesilate on thrombin and plasmin generation after hepatic resection in cirrhotic patients.	Gabexate	10-27	coagulation factor II, thrombin	Homo sapiens	31-39
7890006-0	1995	Effect of gabexate mesilate on thrombin and plasmin generation after hepatic resection in cirrhotic patients.	Gabexate	10-27	plasminogen	Homo sapiens	44-51
7890006-1	1995	The effect of the gabexate mesilate (Gab) on thrombin and plasmin generation following liver resection in cirrhotic patients was studied.	Gabexate	18-35	coagulation factor II, thrombin	Homo sapiens	45-53
7890006-1	1995	The effect of the gabexate mesilate (Gab) on thrombin and plasmin generation following liver resection in cirrhotic patients was studied.	Gabexate	18-35	plasminogen	Homo sapiens	58-65
7890006-1	1995	The effect of the gabexate mesilate (Gab) on thrombin and plasmin generation following liver resection in cirrhotic patients was studied.	Gabexate	37-40	coagulation factor II, thrombin	Homo sapiens	45-53
7890006-1	1995	The effect of the gabexate mesilate (Gab) on thrombin and plasmin generation following liver resection in cirrhotic patients was studied.	Gabexate	37-40	plasminogen	Homo sapiens	58-65
7890006-5	1995	These results show that Gab suppresses plasmin generation and following D-dimer production more effectively than thrombin generation after hepatic resection.	Gabexate	24-27	plasminogen	Homo sapiens	39-46
8666316-3	1996	The induction of IL-6 by IFN-alpha was completely suppressed by the intravenous administration of gabexate mesilate (GM), a serine protease inhibitor.	Gabexate	98-115	interleukin 6	Homo sapiens	17-21
8666316-3	1996	The induction of IL-6 by IFN-alpha was completely suppressed by the intravenous administration of gabexate mesilate (GM), a serine protease inhibitor.	Gabexate	98-115	interferon alpha 1	Homo sapiens	25-34
8666316-3	1996	The induction of IL-6 by IFN-alpha was completely suppressed by the intravenous administration of gabexate mesilate (GM), a serine protease inhibitor.	Gabexate	98-115	coagulation factor II, thrombin	Homo sapiens	124-139
8666316-3	1996	The induction of IL-6 by IFN-alpha was completely suppressed by the intravenous administration of gabexate mesilate (GM), a serine protease inhibitor.	Gabexate	117-119	interleukin 6	Homo sapiens	17-21
8666316-3	1996	The induction of IL-6 by IFN-alpha was completely suppressed by the intravenous administration of gabexate mesilate (GM), a serine protease inhibitor.	Gabexate	117-119	interferon alpha 1	Homo sapiens	25-34
8666316-3	1996	The induction of IL-6 by IFN-alpha was completely suppressed by the intravenous administration of gabexate mesilate (GM), a serine protease inhibitor.	Gabexate	117-119	coagulation factor II, thrombin	Homo sapiens	124-139
8666316-4	1996	The mechanism whereby GM suppresses the elevation in circulating IL-6 levels seems to be the inhibition of IL-6 production at the messenger RNA level.	Gabexate	22-24	interleukin 6	Homo sapiens	65-69
8666316-4	1996	The mechanism whereby GM suppresses the elevation in circulating IL-6 levels seems to be the inhibition of IL-6 production at the messenger RNA level.	Gabexate	22-24	interleukin 6	Homo sapiens	107-111
8666316-5	1996	Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection.	Gabexate	84-86	interferon alpha 1	Homo sapiens	98-107
8666316-5	1996	Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection.	Gabexate	153-155	C-reactive protein	Homo sapiens	25-43
8666316-5	1996	Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection.	Gabexate	153-155	C-reactive protein	Homo sapiens	45-48
8666316-5	1996	Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection.	Gabexate	153-155	interferon alpha 1	Homo sapiens	98-107
8666316-5	1996	Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection.	Gabexate	153-155	interleukin 6	Homo sapiens	171-175
8666316-5	1996	Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection.	Gabexate	153-155	interleukin 6	Homo sapiens	206-210
8666316-5	1996	Elevations of both serum C-reactive protein (CRP) levels and body temperature after GM-suppressed IFN-alpha injection suggest that the administration of GM by suppressing IL-6 production, may attenuate the IL-6-related responses induced by IFN-alpha injection.	Gabexate	153-155	interferon alpha 1	Homo sapiens	240-249
8666316-6	1996	In conclusion, we found that IL-6 was induced by IFN-alpha in vivo, and that this induction was completely abrogated by the administration of GM.	Gabexate	142-144	interleukin 6	Homo sapiens	29-33
8666316-6	1996	In conclusion, we found that IL-6 was induced by IFN-alpha in vivo, and that this induction was completely abrogated by the administration of GM.	Gabexate	142-144	interferon alpha 1	Homo sapiens	49-58
7647905-8	1995	The myeloperoxidase activity in and histological findings of the lung suggested that UT and GM reduced PMN accumulation.	Gabexate	92-94	myeloperoxidase	Rattus norvegicus	4-19
7545361-2	1995	Compared to A, Gabexate Mesilate (FOY) should have the following advantages: lack of antigenicity, low molecular weight with better cellular penetrance, wide inhibitory spectrum (against phospholipase A2 too) and good tolerability.	Gabexate	15-32	phospholipase A2 group IB	Homo sapiens	187-203
8369756-5	1993	Treatment with EGF ointment containing gabexate (GX) or gelatin (GL) ameliorated changes in body weight that occurred after open wound formation, while loss of body weight in animals with open wounds occurred following the application of ointment base, EGF ointment, GX ointment, or GL ointment.	Gabexate	39-47	epidermal growth factor like 1	Rattus norvegicus	15-18
8369756-5	1993	Treatment with EGF ointment containing gabexate (GX) or gelatin (GL) ameliorated changes in body weight that occurred after open wound formation, while loss of body weight in animals with open wounds occurred following the application of ointment base, EGF ointment, GX ointment, or GL ointment.	Gabexate	49-51	epidermal growth factor like 1	Rattus norvegicus	15-18
1916153-6	1991	In vivo, gabexate mesilate, a serine-type protease inhibitor, prevented GalN/TNF-induced fulminant hepatitis, whereas MX-1, an anti-complement agent, had no such effect.	Gabexate	9-26	galanin and GMAP prepropeptide	Rattus norvegicus	72-76
1755340-1	1991	Effects of Gabexate mesilate (GM) (([ethyl-4-(6-guanidino hexanoyloxy) benzoate] methane sulfonate)), a protease inhibitor, on the activities of catalase in liver, erythrocytes and reticulocytes from acatalasemic mice were examined.	Gabexate	11-28	catalase	Mus musculus	145-153
1755340-1	1991	Effects of Gabexate mesilate (GM) (([ethyl-4-(6-guanidino hexanoyloxy) benzoate] methane sulfonate)), a protease inhibitor, on the activities of catalase in liver, erythrocytes and reticulocytes from acatalasemic mice were examined.	Gabexate	30-32	catalase	Mus musculus	145-153
1755340-2	1991	Preincubation without GM at 37 degrees C for 160 min lowered the catalase activities of liver, erythrocytes and reticulocytes from acatalasemic mice, to 24%, 40% and 10% of the initial levels, respectively.	Gabexate	22-24	catalase	Mus musculus	65-73
1755340-5	1991	At pH 5.0, the decrease in catalase activity of acatalasemic mice was small both in the presence and the absence of GM.	Gabexate	116-118	catalase	Mus musculus	27-35
1755340-7	1991	But the presence of GM during preincubation at pH 7.5, retained the catalase activity of acatalasemic mice, to 64% of the activity at pH 6.5.	Gabexate	20-22	catalase	Mus musculus	68-76
1755340-8	1991	These data suggest that some factors affected by GM, might be responsible for the low stability and activity of catalase in the acatalasemic mice.	Gabexate	49-51	catalase	Mus musculus	112-120
1916153-6	1991	In vivo, gabexate mesilate, a serine-type protease inhibitor, prevented GalN/TNF-induced fulminant hepatitis, whereas MX-1, an anti-complement agent, had no such effect.	Gabexate	9-26	tumor necrosis factor-like	Rattus norvegicus	77-80
35412356-13	2022	The present work used a one-compartment pharmacokinetic (PK)/pharmacodynamic (PD) mathematical model for camostat and the active metabolite FOY-251, incorporating TMPRSS2 reversible covalent inhibition by FOY-251, and empirical equations linking TMPRSS2 inhibition of SARS-CoV-2 cell entry.	Gabexate	140-143	transmembrane serine protease 2	Homo sapiens	163-170
2128896-9	1990	The degradation of 125I-EGF in wound tissue homogenate was significantly decreased in the presence of a protease inhibitor, such as nafamostat or gabexate, or gelatin.	Gabexate	146-154	epidermal growth factor	Homo sapiens	24-27
34787160-4	2021	Thus, four potential drugs (bromhexine, camostat, gabexate, and nafamostat) were used to explore the mechanism of binding with TMPRSS2 in this work.	Gabexate	50-58	transmembrane serine protease 2	Homo sapiens	127-134
34787160-6	2021	Through the results of calculating binding free energy by nine methods, the binding affinity of camostat, gabexate, and nafamostat to TMPRSS2 showed great advantages compared with bromhexine, where the nafamostat was surprisingly found to present two reasonable binding conformations (forward and reverse directions).	Gabexate	106-114	transmembrane serine protease 2	Homo sapiens	134-141
34787160-8	2021	In addition, compared with gabexate, the dimethylamino group in camostat forms more van der Waals interactions with surrounding hot-spots His296 and Val280, resulting in a stronger affinity to TMPRSS2.	Gabexate	27-35	transmembrane serine protease 2	Homo sapiens	193-200
1905847-7	1991	Gabexate mesilate, a serine protease inhibitor, suppressed the thrombin inhibition.	Gabexate	0-17	coagulation factor II, thrombin	Bos taurus	63-71
2154054-5	1990	Instead, we now use gabexate mesilate, which blocks the coagulation cascade without the aid of antithrombin III and works as an anticoagulant.	Gabexate	20-37	serpin family C member 1	Homo sapiens	95-111
2109806-7	1990	In one case of HCC complicated with disseminated intravascular coagulation (DIC), t-PA showed a marked increase at acute phase of DIC and subsequent decrease after the successful treatment for DIC by gabexate mesilate (FOY) infusion.	Gabexate	200-217	chromosome 20 open reading frame 181	Homo sapiens	82-86
2467043-0	1989	In vitro inhibition of phospholipase A2 by gabexate mesilate, camostate, and aprotinine.	Gabexate	43-60	phospholipase A2 group IB	Homo sapiens	23-39
2494376-0	1989	Inhibition of porcine pancreas phospholipase A2 activation by gabexate mesilate.	Gabexate	62-79	phospholipase A2 group IB	Homo sapiens	31-47
2494376-1	1989	We investigated the effect of gabexate mesilate on the catalytic activity of phospholipase A2 in homogenized porcine pancreatic tissue.	Gabexate	30-47	phospholipase A2 group IB	Homo sapiens	77-93
2494376-6	1989	Thus gabexate mesilate might influence the activation of phospholipase A2 administered in therapeutic concentrations in inflamed pancreatic tissue.	Gabexate	5-22	phospholipase A2 group IB	Homo sapiens	57-73
3129526-0	1988	Influence of a small molecular weight proteinase inhibitor, gabexate mesilate (FOY), on insulin receptor function in vitro.	Gabexate	60-77	insulin receptor	Homo sapiens	88-104
2496446-8	1989	Moreover, the activity of circulating PLA2 was inhibited in the groups receiving GM.	Gabexate	81-83	phospholipase A2, major isoenzyme	Sus scrofa	38-42
3129526-1	1988	The effects of the low molecular weight serine proteinase inhibitor FOY (gabexate mesilate) upon insulin action was studied in three different experimental systems.	Gabexate	73-90	insulin	Homo sapiens	97-104